Back to Search
Start Over
Trastuzumab deruxtecan in breast cancer.
- Source :
-
Critical Reviews in Oncology/Hematology . Jun2024, Vol. 198, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody covalently linked to a topoisomerase I inhibitor cytotoxic payload (DXd). The high drug-to-antibody ratio (8:1) ensures a high DXd concentration is delivered to target tumour cells, following internalisation of T-DXd and subsequent cleavage of its tetrapeptide-based linker. DXd's membrane-permeable nature enables it to cross cell membranes and potentially exert antitumour activity on surrounding tumour cells regardless of HER2 expression. T-DXd's unique mechanism of action is reflected in its efficacy in clinical trials in patients with HER2-positive advanced breast cancer (in heavily pretreated populations and in those previously treated with a taxane and trastuzumab), as well as HER2-low metastatic breast cancer. Thus, ADCs such as T-DXd have the potential to change the treatment paradigm of targeting HER2 in metastatic breast cancer, including eventually within the adjuvant/neoadjuvant setting. [Display omitted] • Antibody-drug conjugates have significantly improved breast cancer (BC) treatment. • Trastuzumab deruxtecan's (T-DXd) structure allows large payload delivery to targets. • T-DXd has demonstrated unprecedented efficacy in patients with HER2+ advanced BC. • T-DXd has significantly improved survival rates in heavily pretreated BC patients. • T-DXd may change the treatment paradigm of targeting HER2 in metastatic BC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10408428
- Volume :
- 198
- Database :
- Academic Search Index
- Journal :
- Critical Reviews in Oncology/Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 177536796
- Full Text :
- https://doi.org/10.1016/j.critrevonc.2024.104355